Onalespib
- Generic Name
- Onalespib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31N3O3
- CAS Number
- 912999-49-6
- Unique Ingredient Identifier
- Q7Y33N57ZZ
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
- Conditions
- Unresectable High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Primary Peritoneal Serous AdenocarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Primary Peritoneal High Grade Serous AdenocarcinomaRecurrent Triple-Negative Breast CarcinomaRefractory Primary Peritoneal Serous AdenocarcinomaUnresectable Primary Peritoneal Serous AdenocarcinomaMetastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT02898207
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
- Conditions
- Refractory Anaplastic Large Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Mantle Cell LymphomaRefractory Transformed Non-Hodgkin LymphomaRecurrent Anaplastic Large Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT02572453
- Locations
- 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT02503709
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT02474173
- Locations
- 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
- Conditions
- Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT02381535
- Locations
- 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Yale University, New Haven, Connecticut, United States
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Metastatic Malignant Solid NeoplasmStage III Cutaneous Melanoma AJCC v7BRAF V600E Mutation PresentStage IV Cutaneous Melanoma AJCC v6 and v7BRAF V600K Mutation PresentStage IIIB Cutaneous Melanoma AJCC v7Unresectable Solid NeoplasmMetastatic MelanomaStage IIIA Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT02097225
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.